Prostate cancer Cancer Prostate
Conditions
Interventions
Patients are randomised to receive:
1. Treatment A: Bicalutamide 150 mg daily for 35 days plus three oral doses of midazolam 7.5 mg on days 1, 10 and 35.
2. Treatment B
Sponsors
AstraZeneca Clinical Research Group (UK)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically confirmed prostate cancer 2. If surgically orchiectomised following 1 month depot of leutenizing hormone releasing hormone (LHRH) analogue therapy, at least 42 days must elapse from the end of the therapy before entry into the trial. 3. Adequate liver function 4. Not currently receiving drugs which may effect treatment
Exclusion criteria
Exclusion criteria: Patients are excluded if treated with 3 monthly LHRH analogue depots.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed